Novel Immunomodulatory Therapeutics Targeting Neuroinflammation for Alzheimer’s Disease.

Exhibitor: NATIONAL YANG MING CHIAO TUNG UNIVERSITY

Booth No: N726

Characteristic

d. 技術內容簡介 (英文)  Clinical and Industrial Pain Points
Limited efficacy of current antibody treatment: <30% slowing of cognitive decline.
Limited patient eligibility: Primarily applicable to early-stage patients.
Risk of amyloid-related imaging abnormalities (ARIA): ARIA-hemorrhage and ARIA-edema.
Translational gap: Conventional animal models have limited predictive power for clinical outcomes.

 Technology Advantages and Solutions
This technology targets a shared core mechanism driving disease progression—neuroinflammation. By leveraging a cross-platform translational analysis model, it supports the development of disease-modifying therapeutics.
Unlike current therapies that primarily focus on amyloid clearance and have difficulty crossing the blood–brain barrier, this technology features:
• High brain penetrance
• High potency
• High selectivity
It enables precise modulation of microglial activation in the brain, while offering favorable safety and strong potential for long-term treatment.
Preclinical studies demonstrate that this approach can reduce neuroinflammation and neuronal damage, and improve cognitive function.